1. Pink Sheet

10 Things For Pfizer's New CEO To Worry About

 
• By Bridget Silverman

Albert Bourla will face opportunities and potential pitfalls.

Albert Bourla
Albert Bourla takes the CEO reins at Pfizer Jan. 1.

When Albert Bourla succeeds Ian Read as Pfizer Inc.'s CEO on Jan. 1, he'll take over the world's largest pharmaceutical company at a time when it enjoys several strong growth drivers (Eliquis, Ibrance, Xeljanz and Xtandi) but faces equally potent challenges in its key product areas.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

New EU Filings

 
• By Neena Brizmohun

Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.